ARGNF News and Press, Argen X SE From 02/19/26

February 19, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, Febr...

2026-02-19 00:30:00 ET The following segment was excerpted from the Allspring Large Cap Growth Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Allspring Large Cap Growth Fund Q4 2025 Performance Update

2026-02-12 21:15:00 ET The following segment was excerpted from the Allspring Growth Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Allspring Growth Fund Q4 2025 Fund Performers And Detractors

2026-01-19 22:30:00 ET The following segment was excerpted from the Artisan Mid Cap Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portf...

January 13, 2026, 7:00 AM CET  Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) ...

2026-01-12 14:06:01 ET argenx SE (ARGX) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 11:15 AM EST... Read the full article on Seeking Alpha For further details see: argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end o...

January 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 4...

2026-01-05 07:46:14 ET More on argenx SE Argenx: TED Phase 3 Failure, Vyvgart Growth, And Why I'm Still A Hold argenx: Sights Set On $1,000 argenx SE (ARGX) Q3 2025 Earnings Call Transcript Argenx cut to Neutral at Baird after trial setback for Vyvgart ...

Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a glob...